Malignant melanoma is a neoplasm of melanocytes, and the microphthalmia‐associated
transcription factor (MITF) is essential for the existence of melanocytes. MITF's relevance for …

The Mitogen Activated Protein Kinase (MAPK) pathway plays a key role in melanoma
development making it an important therapeutic target. In normal cells, the tightly regulated …

Pediatric low-grade gliomas (pLGG) show heterogeneous responses to MAPK inhibitors
(MAPKi) in clinical trials. Thus, more complex stratification biomarkers are needed to identify …

We elucidated genomic and transcriptomic changes that accompany the evolution of
melanoma from pre-malignant lesions by sequencing DNA and RNA from primary …

Purpose The prevalence of BRAF, NRAS, and p16CDKN2A mutations during melanoma
progression remains inconclusive. We investigated the prevalence and distribution of …

KRAS-and BRAF-mutant tumors are often dependent on MAPK signaling for proliferation
and survival and thus sensitive to MAPK pathway inhibitors. However, clinical studies have …

BACKGROUND. Constitutive activation of ERK1/2 occurs in various cancers, and its
reactivation is a well-described resistance mechanism to MAPK inhibitors. ERK inhibitors …

Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors characterized by
mutations of KIT or PDGFRA. The objectives of this study were to evaluate BRAF mutations …

Relatively little is known about the molecular changes that promote the formation or growth
of pilocytic astrocytomas. We investigated genomic alterations in 25 pilocytic astrocytomas …

Here, we identify a panel of melanoma lines with non-V600E mutations in BRAF. These
G469E-and D594G-mutated melanomas were found to exhibit constitutive levels of phospho …